Advancing cardiovascular outcomes with dapagliflozin and sacubitril in post-acute myocardial infarction heart failure and type 2 diabetes mellitus

doi:10.12998/wjcc.v12.i36.6935

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 36

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8)

All Articles published online

The chart showing PDF series, WORD series, HTML series.

Item

Count

PDF

WORD

HTML

Sum=8

Dec 26, 2024 (publication date) through Oct 31, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Clin Cases. Dec 26, 2024; 12(36): 6935-6938
Published online Dec 26, 2024. doi: 10.12998/wjcc.v12.i36.6935

Advancing cardiovascular outcomes with dapagliflozin and sacubitril in post-acute myocardial infarction heart failure and type 2 diabetes mellitus

Dong-Hua Liu, Xiao-Ming Dong, Wen-Jie Long

Dong-Hua Liu, The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China

Xiao-Ming Dong, Wen-Jie Long, Department of Geriatrics, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China

Author contributions: Long WJ conceived the idea; Liu DH and Dong XM conducted a literature search; Liu DH wrote the preliminary draft; Dong XM and Long WJ critically reviewed as well as improved the manuscript; all authors have read and approved the final manuscript.

Supported by the Scientific Research Project of Guangdong Provincial Bureau of Traditional Chinese Medicine, No. 2022ZYYJ01; and Guangzhou Municipal Science and Technology Bureau's 2024 Basic and Applied Basic Research Topic, No. 2024A04J4254.

Conflict-of-interest statement: There are no conflict-of-interest disclosures by any authors.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Wen-Jie Long, MD, PhD, Doctor, Department of Geriatrics, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 12 Jichang Road, Guangzhou 510405, Guangdong Province, China. lwj5699@gzucm.edu.cn

Received: July 7, 2024
Revised: September 18, 2024
Accepted: October 22, 2024
Published online: December 26, 2024
Processing time: 115 Days and 13.2 Hours

Core Tip

Core Tip: This study highlights the combined use of dapagliflozin and sacubitril in patients with post-acute myocardial infarction heart failure and type 2 diabetes. The observed improvements in myocardial microcirculation, cardiac function, and glycemic control were significant, alongside a reduced incidence of major adverse cardiovascular events. The findings underscore the potential synergistic benefits of this therapeutic combination; however, long-term outcomes require further investigation. The results support the need for personalized treatment strategies to enhance cardiovascular care in this high-risk patient group.